Determination of two HMG-CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatography–tandem mass spectrometry for pharmaceutical study

2008 ◽  
Vol 22 (2) ◽  
pp. 131-135 ◽  
Author(s):  
Jian-Wei Deng ◽  
Kwon-Bok Kim ◽  
Im-Sook Song ◽  
Ji-Hong Shon ◽  
Hong-Hao Zhou ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Liquid Chromatography ◽  
Tandem Mass ◽  
Plasma Samples ◽  
Reductase Inhibitors ◽  
Chromatography Tandem Mass Spectrometry ◽  
Liquid Chromatography Tandem Mass ◽  
Hmg Coa Reductase Inhibitors ◽  
Coa Reductase

scholarly journals Quality by Design–Applied Liquid Chromatography-Tandem Mass Spectrometry Determination of Enzalutamide Anti-Prostate Cancer Therapy Drug in Spiked Plasma Samples

2017 ◽  
Vol 12 ◽  
pp. 117739011772677 ◽  
Author(s):  
ASK Sankar ◽  
Shanmugasundaram Palani ◽  
Ravichandiran Velayudham
Keyword(s):  
Mass Spectrometry ◽  
Liquid Chromatography ◽  
Tandem Mass Spectrometry ◽  
Quality By Design ◽  
Tandem Mass ◽  
Plasma Samples ◽  
Chromatography Tandem Mass Spectrometry ◽  
Spiked Plasma ◽  
Liquid Chromatography Tandem Mass

This research article presents the Quality by Design (QbD)–finalised conditions for a method that uses liquid chromatography-tandem mass spectrometry for the determination of concentration of enzalutamide (ENZ), an atypical anticancer drug, in a drug formulation and in spiked plasma samples. Critical process attributes (CPA) considered to be the influential parameters in separation, identification, and quantification processes by ultrahigh-performance liquid chromatography-electrospray ionisation-tandem mass spectrometry (UHPLC-ESI-MS/MS) were organic content, buffer strength, pH modifier, flow rate, spray voltage, sheath gas, and auxiliary gas that alter critical analytical attributes, such as retention time (R1) and area (R2). These factors were evaluated first in a factorial design (Taguchi orthogonal array design) and then extensively in a central composite design (CCD) to zero-in on the mobile phase for the quantification of ENZ standard drug and along with its internal standard (ENZIS) in spiked plasma samples and in formulation. Pareto chart from initial factorial design (Taguchi orthogonal array design) model suggested which of the CPA factors should be given the weightage, that is, to be exhaustively analysed in the CCD and response surface analysis. The elaborated parameters proposed by World Health Organization were studied by method validation, ie, selectivity, linearity, accuracy, precision repeatability system-suitability tests, method robustness/ruggedness, sensitivity, and stability. The strategy followed gives an insight on the development of a robust QbD-compliant quantitative UHPLC-ESI-MS/MS method for ENZ drug containing plasma samples (spiked).

scholarly journals Determination of rivaroxaban in patient’s plasma samples by anti-Xa chromogenic test associated to High Performance Liquid Chromatography tandem Mass Spectrometry (HPLC-MS/MS)

PLoS ONE ◽  
2017 ◽  
Vol 12 (2) ◽  
pp. e0171272 ◽  
Author(s):  
Priscilla Bento Matos Derogis ◽  
Livia Rentas Sanches ◽  
Valdir Fernandes de Aranda ◽  
Marjorie Paris Colombini ◽  
Cristóvão Luis Pitangueira Mangueira ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
High Performance Liquid Chromatography ◽  
Liquid Chromatography ◽  
Tandem Mass Spectrometry ◽  
High Performance ◽  
Tandem Mass ◽  
Plasma Samples ◽  
Chromatography Tandem Mass Spectrometry ◽  
Liquid Chromatography Tandem Mass
Sign in / Sign up

Export Citation Format

Share Document